Keros Therapeutics, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $40.0 million (+180.5% year over year) and diluted EPS of $0.70. It usually reports 34–63 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 3, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Mar 4, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 34–63 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
40
+180.5%
|
14
+294.4%
|
0.70
+488.9%
|
|
Aug 3, 2026
34 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
-100.0%
|
-29
+6.5%
|
-1.45
-90.8%
|
|
May 14, 2026
44 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
-99.8%
|
-24
-116.0%
|
-1.21
-133.4%
|
|
Mar 4, 2026
63 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
0
-87.3%
|
-23
+49.0%
|
-0.84
+26.5%
|
|
Oct 15, 2025
15 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
14
+3575.8%
|
-7
+86.3%
|
-0.18
+87.2%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
18
+49002.7%
|
-31
+32.2%
|
-0.76
+39.2%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
211
+254413.3%
|
148
+444.3%
|
3.62
+399.2%
|
|
Feb 26, 2025
57 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
3
+2027.3%
|
-46
-14.4%
|
-1.14
+14.6%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KROS (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Lexington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1664710
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.